Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients
Abstract This retrospective study compared the efficacy and safety of nedaplatin-based chemoradiotherapy and cisplatin-based chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma (NPC) patients. Patients treated with cisplatin-based or nedaplatin-based chemoradiotherapy between January 2012 and...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-16216-0 |
| _version_ | 1828267723878039552 |
|---|---|
| author | Chao Deng Na Zhang Shun Jiang Haixia Zhang Jin’an Ma Wen Zou Xianling Liu Chunhong Hu Tao Hou |
| author_facet | Chao Deng Na Zhang Shun Jiang Haixia Zhang Jin’an Ma Wen Zou Xianling Liu Chunhong Hu Tao Hou |
| author_sort | Chao Deng |
| collection | DOAJ |
| description | Abstract This retrospective study compared the efficacy and safety of nedaplatin-based chemoradiotherapy and cisplatin-based chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma (NPC) patients. Patients treated with cisplatin-based or nedaplatin-based chemoradiotherapy between January 2012 and December 2015 were evaluated. Survival was estimated by the Kaplan‒Meier method and compared by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. A cohort of 538 NPC patients was enrolled. There were no significant differences in the 5-year overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), or distant metastasis-free survival (DMFS) between the cisplatin and nedaplatin groups. During the whole treatment course, patients in the cisplatin group had higher incidences of grade 3‒4 vomiting and anorexia, while patients in the nedaplatin group had higher incidences of grade 3‒4 leucopenia and mucositis. In terms of late toxicities, patients in the cisplatin group had a higher incidence of xerostomia. In multivariate analysis, T stage, N stage, and clinical stage were prognostic factors for OS, PFS, and DMFS. In subgroup analyses, nedaplatin-based chemotherapy achieved comparable treatment outcomes in specific populations stratified by age, sex, ECOG PS score and clinical stage. Cisplatin and nedaplatin are effective choices for stage II-IVa NPC patients, with a different spectrum of side effects. |
| first_indexed | 2024-04-13T05:08:16Z |
| format | Article |
| id | doaj.art-779f881877b24d9ca5aa15c571592c81 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-13T05:08:16Z |
| publishDate | 2022-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-779f881877b24d9ca5aa15c571592c812022-12-22T03:01:07ZengNature PortfolioScientific Reports2045-23222022-07-0112111010.1038/s41598-022-16216-0Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patientsChao Deng0Na Zhang1Shun Jiang2Haixia Zhang3Jin’an Ma4Wen Zou5Xianling Liu6Chunhong Hu7Tao Hou8Department of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityDepartment of Oncology, The Second Xiangya Hospital, Central South UniversityAbstract This retrospective study compared the efficacy and safety of nedaplatin-based chemoradiotherapy and cisplatin-based chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma (NPC) patients. Patients treated with cisplatin-based or nedaplatin-based chemoradiotherapy between January 2012 and December 2015 were evaluated. Survival was estimated by the Kaplan‒Meier method and compared by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. A cohort of 538 NPC patients was enrolled. There were no significant differences in the 5-year overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), or distant metastasis-free survival (DMFS) between the cisplatin and nedaplatin groups. During the whole treatment course, patients in the cisplatin group had higher incidences of grade 3‒4 vomiting and anorexia, while patients in the nedaplatin group had higher incidences of grade 3‒4 leucopenia and mucositis. In terms of late toxicities, patients in the cisplatin group had a higher incidence of xerostomia. In multivariate analysis, T stage, N stage, and clinical stage were prognostic factors for OS, PFS, and DMFS. In subgroup analyses, nedaplatin-based chemotherapy achieved comparable treatment outcomes in specific populations stratified by age, sex, ECOG PS score and clinical stage. Cisplatin and nedaplatin are effective choices for stage II-IVa NPC patients, with a different spectrum of side effects.https://doi.org/10.1038/s41598-022-16216-0 |
| spellingShingle | Chao Deng Na Zhang Shun Jiang Haixia Zhang Jin’an Ma Wen Zou Xianling Liu Chunhong Hu Tao Hou Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients Scientific Reports |
| title | Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients |
| title_full | Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients |
| title_fullStr | Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients |
| title_full_unstemmed | Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients |
| title_short | Nedaplatin-based chemotherapy or cisplatin-based chemotherapy combined with intensity-modulated radiotherapy achieve similar efficacy for stage II-IVa nasopharyngeal carcinoma patients |
| title_sort | nedaplatin based chemotherapy or cisplatin based chemotherapy combined with intensity modulated radiotherapy achieve similar efficacy for stage ii iva nasopharyngeal carcinoma patients |
| url | https://doi.org/10.1038/s41598-022-16216-0 |
| work_keys_str_mv | AT chaodeng nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT nazhang nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT shunjiang nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT haixiazhang nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT jinanma nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT wenzou nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT xianlingliu nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT chunhonghu nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients AT taohou nedaplatinbasedchemotherapyorcisplatinbasedchemotherapycombinedwithintensitymodulatedradiotherapyachievesimilarefficacyforstageiiivanasopharyngealcarcinomapatients |